ライフサイエンスコーパス: Kaplan

1 Kaplan and colleagues recently demonstrated that a semis

2 Kaplan-Meier 3-year post-LT survival was 83.2% for Milan

3 Kaplan-Meier 5-year estimates of MACCE were 28% (165 eve

4 Kaplan-Meier 5-year post-LT survival for those with AFP

5 Kaplan-Meier age-adjusted 5-year probability of death in

6 Kaplan-Meier analyses and multivariable proportional haz

7 Kaplan-Meier analyses assessed time to first chart-docum

8 Kaplan-Meier analyses compared long-term patient and dea

9 Kaplan-Meier analyses revealed that high DDX21 protein l

10 Kaplan-Meier analyses were performed to evaluate event-f

11 Kaplan-Meier analysis according to low, intermediate, an

12 Kaplan-Meier analysis and Cox proportional hazards model

13 Kaplan-Meier analysis and multivariable Cox proportional

14 Kaplan-Meier analysis and proportional hazard regression

15 Kaplan-Meier analysis demonstrated an increased risk of

16 Kaplan-Meier analysis of 1582 eyes that underwent incisi

17 Kaplan-Meier analysis of PET/CT-based staging showed pro

18 Kaplan-Meier analysis revealed that 5- and 10-year patie

19 Kaplan-Meier analysis showed that patients with GDS>0.86

20 Kaplan-Meier analysis showed that the 50% of the fellow

21 Kaplan-Meier analysis was performed to calculate progres

22 Kaplan-Meier analysis was used to compare graft and pati

23 Kaplan-Meier analysis was used to further explore the as

24 Kaplan-Meier analysis with log-rank was used to determin

25 Kaplan-Meier and Cox proportional hazard models were use

26 Kaplan-Meier and Cox proportional hazards regression ana

27 Kaplan-Meier and Cox regression analyses for the overall

28 Kaplan-Meier and Cox regression analyses were used.

29 Kaplan-Meier and landmark Cox Regression models were use

30 Kaplan-Meier and log-rank methods were used to test pred

31 Kaplan-Meier curve was used to examine cumulative risk f

32 Kaplan-Meier curves and Cox proportional hazards models

33 Kaplan-Meier curves and multivariable Cox proportional h

34 Kaplan-Meier curves plot the duration of effect.

35 Kaplan-Meier curves showed a significant higher 30-day m

36 Kaplan-Meier curves showed patients with forced expirato

37 Kaplan-Meier curves were constructed to examine median t

38 Kaplan-Meier curves were generated for survival analysis

39 Kaplan-Meier curves were generated to compare the cumula

40 Kaplan-Meier curves were plotted to compare survival rat

41 Kaplan-Meier estimate of metastasis developing was 15% (

42 Kaplan-Meier estimated freedom from PGTCS at end of the

43 Kaplan-Meier estimates in the RCTs were compared with re

44 Kaplan-Meier estimates of 8-year freedom from distant re

45 Kaplan-Meier estimates of claims-defined versus trial-de

46 Kaplan-Meier estimates of overall survival (OS) and even

47 Kaplan-Meier estimates of overall survival at 3 years we

48 Kaplan-Meier estimates of primary patency were 79% and 8

49 Kaplan-Meier estimates showed a lower rate of death (12.

50 Kaplan-Meier estimates were calculated for clinically si

51 Kaplan-Meier estimator was used to assess survival strat

52 Kaplan-Meier estimators and log rank test were used to c

53 Kaplan-Meier event rates were assessed for the primary e

54 Kaplan-Meier lifetable probabilities of incident diagnos

55 Kaplan-Meier method and multivariable Cox proportional h

56 Kaplan-Meier method, log-rank test, and Cox model were u

57 Kaplan-Meier methods were used to determine median time

58 Kaplan-Meier survival analyses were used to compare the

59 Kaplan-Meier survival analysis and Cox proportional haza

60 Kaplan-Meier survival analysis and Cox proportional haza

61 Kaplan-Meier survival analysis estimated a better globe

62 Kaplan-Meier survival analysis revealed that high G9a ex

63 Kaplan-Meier survival at 1 year was 72% without interven

64 Kaplan-Meier survival curves and Cox regression revealed

65 Kaplan-Meier survival curves and the Wilcoxon test were

66 Kaplan-Meier survival curves of OSSN recurrence were sim

67 Kaplan-Meier survival curves showed an increased number

68 Kaplan-Meier survival curves were generated by treatment

69 Kaplan-Meier survival estimates were used to assess the

70 Kaplan-Meier survival rates at 5 years of follow-up were

71 Kaplan-Meier survival through 7 years was 51%.

72 .1% (95% confidence interval [CI] 91.4-98.2; Kaplan-Meier).

73 A Kaplan-Meier estimate with a univariate model determined

74 A Kaplan-Meier survival analysis was also conducted.

75 In this case, a Kaplan-Meier survival curve for a specific cause that tr

76 dure or drug dose adjustment, evaluated in a Kaplan-Meier analysis).

77 iagnoses were obtained and used to perform a Kaplan-Meier analysis.

78 We recently performed a Kaplan-Meier survival analysis of naked mole-rats (Heter

79 We estimated survival probabilities using a Kaplan-Meier estimator, and a relative risk of patient a

80 Cox regression analysis, Kaplan-Meier curves, and cross-validated receiver operat

81 racteristic curve analysis (p = 0.00137) and Kaplan-Meier survival method (p = 0.0029, brain metastas

82 Cox regression analysis and Kaplan-Meier curves were used for analysis.

83 e used to reconstruct clonal composition and Kaplan-Meier-like survival curves of multiple evolutiona

84 act test assessed associations with CTR, and Kaplan-Meier/Cox methods assessed associations with OS f

85 n model for recurrent time-to-event data and Kaplan-Meier curves for time to antibody negativity were

86 ransplant, and hepatoma) were evaluated, and Kaplan-Meier survival estimates and Cox proportional haz

87 es were evaluated by proteome microarray and Kaplan-Meier survival analysis was used to determine sur

88 The Cox proportional-hazards model and Kaplan-Meier curve were used to evaluate the association

89 g both the Cox proportional hazard model and Kaplan-Meier curves each show that the proposed method f

90 l RNA shedding using logistic regression and Kaplan-Meier analyses.

91 RECIST) were evaluated by Cox regression and Kaplan-Meier statistics.

92 score-matched, survival (Cox regression and Kaplan-Meier), and center effects analyses were performe

93 with overall survival (OS) from relapse and Kaplan-Meier statistics.

94 timal cutoff for quantitative variables, and Kaplan-Meier survival analyses were performed.

95 Mixed-model analysis of variance and Kaplan-Meyer method was accessed, as appropriate.

96 We applied Kaplan-Meier statistics to assess unadjusted survival.

97 At Kaplan-Meier analysis, patients with LV involvement (LV

98 At Kaplan-Meier curves, patients with LGE and without edema

99 rvival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event e

100 Survival was analyzed by Kaplan-Meier method.

101 urrence-free survival (BRFS) was assessed by Kaplan-Meier analysis and log rank test.

102 n SNB only vs SNB + AD patients, assessed by Kaplan-Meier and compared using log-rank test, with use

103 ase of >=10 mm Hg over baseline) assessed by Kaplan-Meier and proportional hazards analyses, taking l

104 was primary patency at 12 months assessed by Kaplan-Meier.

105 uity, 5-year treatment-success calculated by Kaplan-Meier analysis was only 38.4%.

106 and bone metastasis statuses was compared by Kaplan-Meier analysis.

107 and bone metastasis statuses was compared by Kaplan-Meier analysis.

108 Survival of the fellow eye was estimated by Kaplan-Meier analysis, and log-rank test was used to com

109 e to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for fir

110 t and cumulative incidence were evaluated by Kaplan-Meier analysis, and relative risks were estimated

111 ase activity-free intervals was evaluated by Kaplan-Meier estimates.

112 HCC occurrence rates were evaluated by Kaplan-Meier.

113 t macular atrophy after nAMD was examined by Kaplan-Meier analysis and proportional hazards regressio

114 ropensity-matched cohorts and illustrated by Kaplan-Meier analysis with subgroup analysis for intermi

115 umulative incidence of advanced neoplasia by Kaplan-Meier curves.

116 (2009-2019), comparing survival outcomes by Kaplan-Meier analysis and comparing other measures of ou

117 We calculated Kaplan-Meier curves and used adjusted Cox proportional-h

118 % in treated patients and 35.6% in controls (Kaplan-Meier plots, P = .005).

119 The area under the curve of a conventional Kaplan-Meier curve applied to the observed data was comp

120 rank tests were performed, and corresponding Kaplan-Meier survival plots were generated.

121 gnitive inhibition, assessed using the Delis-Kaplan Executive Function System Color-Word Interference

122 r events compared to patients with dilation (Kaplan-Meier Log rank; P < 0.05).

123 The area under each Kaplan-Meier curve was estimated by the 36-month restric

124 rable outcome derived from the time-to-event Kaplan-Meier curve at 10 years was 0.64 (95% CI 0.58-0.6

125 point events occurred in the ablation group (Kaplan-Meier estimate of the percentage of patients with

126 However, Kaplan-Meier analysis indicated a longer survival time i

127 In Kaplan-Meier analysis, MTA1dE4 overexpression in tumor,

128 In Kaplan-Meier analysis, patients whose tumours were CCS L

129 In Kaplan-Meier plots by treatment regimen, those treated w

130 er or not there is evidence for such bias in Kaplan-Meier estimates of survival probabilities for car

131 C index = 0.724, p < 0.001) and mortality in Kaplan-Meier analysis (p < 0.001).

132 having 1.5% and 2.7% absolute reductions in Kaplan-Meier estimates of HHF risk at 4 years, respectiv

133 Statistical analysis included Kaplan-Meier survival curves and Cox regression.

134 Analysis methods included Kaplan-Meier and Cox proportional hazards.

135 Indeed, Kaplan-Meier survival analysis for patients with pancrea

136 We used landmark Kaplan-Meier and Cox regression models to analyse the as

137 Cox proportional hazard models, Kaplan-Meier curves, and z scores were applied to assess

138 We used a modified Kaplan-Meier analysis, accounting for the competing risk

139 The 12-month Kaplan-Meier estimate of freedom from arrhythmia was 87.

140 d 42 patients in the control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respec

141 236 patients in the control group (12-month Kaplan-Meier estimated event rate, 6.0% and 6.9%, respec

142 The 24-month Kaplan-Meier progression-free percentages were 43.5% [95

143 ients in the transvenous ICD group (48-month Kaplan-Meier estimated cumulative incidence, 15.1% and 1

144 At a median follow-up of 36 months, Kaplan-Meier overall survival at 1, 3, and 5 years were

145 In this issue of Neuron, Kaplan et al.

146 We obtained Kaplan-Meier estimates with bootstrapped confidence inte

147 ar overall survival were estimated by use of Kaplan-Meier methods, and the 5-year cumulative incidenc

148 On Kaplan-Meier analysis, patients with dysfunction grade I

149 =0.0050) and lower likelihood of survival on Kaplan-Meier analysis (hazard ratio 5.9, 95% CI 1.9-18.4

150 l (0.54; 95% CrI, 0.37-0.75) or the original Kaplan-Meier estimate (0.55; 95% CI, 0.40-0.74).

151 At 3 years, the overall Kaplan-Meier estimate of all-cause mortality was 32.7%.

152 The overall Kaplan-Meier estimate of PCR-corrected efficacy of dihyd

153 The overall Kaplan-Meier graft survival rates were 64.7% in the post

154 150 of 300 patients vs 156 of 296 patients (Kaplan-Meier estimator percentages, 51.2% vs 53.6%; unad

155 For the PC1, Kaplan-Meier plots showed a significant difference betwe

156 les across a cohort, RTNsurvival can perform Kaplan-Meier analyses and Cox Proportional Hazards regre

157 ficantly lower with lacosamide than placebo (Kaplan-Meier survival estimates 55.27%/33.37%; HR 0.540,

158 on revascularization when compared with PTA (Kaplan-Meier estimate of 74.5% versus 65.3%; log-rank P=

159 atients was reconstructed from the published Kaplan-Meier curves with the aid of a computer vision pr

160 e evaluated using linear and Cox regression, Kaplan-Meier survival, and mediation analyses.

161 Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression

162 e evaluated with competing risks regression, Kaplan-Meier analysis, and Cox proportional hazards regr

163 atients met the primary endpoint of relapse (Kaplan-Meier estimate of event rate 36.0% [95% CI 20.6-5

164 Median follow-up was analyzed by reverse Kaplan-Meier.

165 6-patient pooled nonrandomized DCB data set (Kaplan-Meier estimates of 2.1%, 4.9%, and 7.0% at 1, 2,

166 at, while it is clear that the gold standard Kaplan model is driven by GC content (by design) and by

167 Descriptive statistics, Kaplan-Meier survival curves and Cox proportional hazard

168 The Kaplan Meier (KM) curves between the two clusters differ

169 The Kaplan-Meier (KM) estimator of the survival function imp

170 The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the pa

171 The Kaplan-Meier analysis revealed the contraceptive vaginal

172 The Kaplan-Meier curves of TIA patients with DAPT and monoth

173 The Kaplan-Meier estimate of freedom from cardiovascular hos

174 The Kaplan-Meier estimate of overall survival at 36 months w

175 The Kaplan-Meier estimate of proportion of patients undergoi

176 The Kaplan-Meier estimate of the 36-month rate of overall su

177 The Kaplan-Meier estimate of the percentage of patients with

178 The Kaplan-Meier estimate of the rate of the primary composi

179 The Kaplan-Meier estimator, U test, and Cox regression analy

180 The Kaplan-Meier method was used to construct survival curve

181 At 1 year, there were 139 deaths, and the Kaplan-Meier estimate of freedom from mortality was 76.8

182 analyses were by intention to treat and the Kaplan-Meier method to estimate event rates.

183 for competing risks was calculated; and the Kaplan-Meier method was used to analyze the importance o

184 ere analysed using the Poisson model and the Kaplan-Meier method, respectively.

185 ery rate (q) and logistic regression and the Kaplan-Meier method, respectively.

186 We applied the Kaplan-Meier method to estimate survival probabilities a

187 ed survival analysis techniques, such as the Kaplan-Meier method, often are not appropriate for such

188 mpared with usual care, as determined by the Kaplan-Meier method (ICU survivor care 0.89 vs usual car

189 comparison of survival was performed by the Kaplan-Meier method with the log-rank test.

190 CC recurrence incidence were compared by the Kaplan-Meier method.

191 are also informative and can complement the Kaplan model.

192 llograft survival was analyzed employing the Kaplan-Meier method.

193 We found that survival estimates from the Kaplan-Meier curves were largely congruent with those of

194 n group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were

195 In the Kaplan-Meier analysis, individuals within the lowest ter

196 After a median follow-up of 36 months, the Kaplan-Meier estimates of PFS were 86% (95% confidence i

197 rgery was calculated for illustration of the Kaplan-Meier curves.

198 Survival analysis performed based on the Kaplan-Meier method and Mantel-Cox test.

199 y blastoma and thyroid nodules), we used the Kaplan-Meier method and nonparametric cumulative inciden

200 We used the Kaplan-Meier method to determine the 30-day probability

201 me-to-event analysis was performed using the Kaplan-Meier estimator and life table.

202 d overall survival (OS), estimated using the Kaplan-Meier method and compared using Cox models adjust

203 ifferent indications was estimated using the Kaplan-Meier method and compared using the log-rank test

204 OS was estimated using the Kaplan-Meier method and log-rank test.

205 OS were analyzed using the Kaplan-Meier method and the log-rank test.

206 Overall survival (OS) was analyzed using the Kaplan-Meier method and the log-rank test.

207 1,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multi

208 Median OS measured by using the Kaplan-Meier method was 17 months from diagnosis of loca

209 Overall survival was calculated using the Kaplan-Meier method with the log-rank test.

210 ival probabilities were calculated using the Kaplan-Meier method, and the association of covariates w

211 Overall survival was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional haz

212 inal discontinuation were assessed using the Kaplan-Meier method.

213 lue of (18)F-FET PET was estimated using the Kaplan-Meier method.

214 Three-year survival was estimated using the Kaplan-Meier method.

215 me-to-event curves were calculated using the Kaplan-Meier method.

216 etention time (DRT) were estimated using the Kaplan-Meier method.

217 transplant survival was performed using the Kaplan-Meier method.

218 Survival data were obtained using the Kaplan-Meier method.

219 mortality estimates were estimated using the Kaplan-Meier method.

220 erall survival (OS) were estimated using the Kaplan-Meier method.

221 ting, and described time-to-report using the Kaplan-Meier method.

222 We analyzed survival using the Kaplan-Meier method.

223 HLA-sensitized (non-HS) recipients using the Kaplan-Meier product-limit method.

224 HLA sensitized (non-HS) recipients using the Kaplan-Meier product-limit method.

225 Cumulative survival via the Kaplan-Meier method was significantly lower in the hypoc

226 The mean survival time with the Kaplan-Mayer analysis was 109.9 months (9.1 years).

227 The 5-y mortality rate obtained with the Kaplan-Meier (KM) method was estimated to be 10.1% highe

228 cumulative incidence function curve with the Kaplan-Meier curve.

229 final discontinuation were assessed with the Kaplan-Meier method, with Cox proportional hazard models

230 rence-free survivals were estimated with the Kaplan-Meier method.

231 ver-related events were investigated through Kaplan-Meier and Cox regression analyses, respectively.

232 We find additional support through Kaplan-Meier survival curves of thousands of patients.

233 ned from the training cohort, in addition to Kaplan-Meier analysis including the log-rank test.

234 fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovaria

235 We also did intention-to-treat Kaplan-Meier life table analyses and followed up women w

236 ention effect was estimated using unadjusted Kaplan-Meier survival curves and a Cox proportional haza

237 Statistics comprised univariable Kaplan-Meier and multivariable Cox regression analyses i

238 sions by anatomical site of surgery and used Kaplan-Meier analyses to assess differences in survival

239 00/muL or with acute HIV infection) and used Kaplan-Meier plots and proportional hazards regression t

240 We further used Kaplan-Meier curves and Cox regression to assess differe

241 those with missing CSRS predictors, we used Kaplan-Meier analysis to describe the time to serious ar

242 We used Kaplan-Meier analysis to estimate survival rates and Cox

243 We used Kaplan-Meier curves and hazard ratios (HRs) for time to

244 We used Kaplan-Meier estimators for survival probabilities and c

245 We used Kaplan-Meier methods and Cox regression to describe the

246 Using Kaplan-Meier analysis, inducible ischemia and late gadol

247 Using Kaplan-Meier curves and the log-rank test, we compared m

248 Using Kaplan-Meier survival estimates and Cox proportional haz

249 DFS and OS were analyzed using Kaplan-Meier curves and multiple Cox regression.

250 Survival rates were analyzed using Kaplan-Meier estimate.

251 othelial dystrophy (FED) were analyzed using Kaplan-Meier survival curves with log-rank test and Cox

252 activation of the lesion were analyzed using Kaplan-Meier survival curves.

253 Patient survival was assessed using Kaplan-Meier curves analysis.

254 Oncological outcome was assessed using Kaplan-Meier estimates.

255 hospital characteristics were assessed using Kaplan-Meir methodology and Cox regression analysis adju

256 lant-free survival was investigated by using Kaplan-Meier analysis, log-rank tests, and Cox regressio

257 ree survival (LPFS) were calculated by using Kaplan-Meier analysis.

258 d overall recurrence were evaluated by using Kaplan-Meier analysis.

259 tures and 5-year OS were determined by using Kaplan-Meier estimators using the log-rank test and mult

260 Time to recurrence was calculated using Kaplan Meier estimates.

261 Net failure was calculated using Kaplan-Meier estimates, and adjusted analyses employed f

262 and stage-based survival were compared using Kaplan-Meier analysis, Cox proportional-hazards regressi

263 n 432 RBD patients with available data using Kaplan-Meier survival analysis.

264 Survival was determined using Kaplan-Meier method.

265 Overall survival (OS) was estimated using Kaplan-Meier and log-rank tests.

266 al after transplantation was estimated using Kaplan-Meier method and logistic regression to identify

267 ase-free survival (DFS) were estimated using Kaplan-Meier methods, and a multivariable Cox proportion

268 me-to-endpoint analyses were estimated using Kaplan-Meier.

269 to 30 years of follow-up was evaluated using Kaplan-Meier analyses for those with mean non-HDL-C >=16

270 Survival was evaluated using Kaplan-Meier analysis, and Cox proportional hazards mode

271 the synthetic lethal gene is evaluated using Kaplan-Meier analysis.

272 overall survival, which was evaluated using Kaplan-Meier and multivariable Cox Proportional Hazards

273 e-bleeding free survival was evaluated using Kaplan-Meier curves with log rank test, whilst predictor

274 rogression-free survival was evaluated using Kaplan-Meier estimates and a Cox proportional hazards re

275 OS was evaluated using Kaplan-Meier tests.

276 recurrence free survival were explored using Kaplan-Meier analysis.

277 Survival curves were generated using Kaplan-Meier method, and comparison between two independ

278 We assessed 5-year mortality using Kaplan-Meier and Cox proportional hazards models adjuste

279 d between responders and nonresponders using Kaplan-Meier and log-rank analyses.

280 OS and DFS analyses were performed using Kaplan-Meier curves and Cox proportional hazard models.

281 We estimated time to first pregnancy using Kaplan-Meier curves; pregnancy and HIV incidence were es

282 ll as hospital and ICU discharge rates using Kaplan-Meier estimation and weighted Cox proportional ha

283 atient and graft survival were studied using Kaplan-Meier method, log-rank test.

284 e evaluated patient and graft survival using Kaplan-Meier and Fleming-Harrington weighted log-rank te

285 me to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression.

286 At 1 year using Kaplan-Meier life-table estimation, the transcarotid app

287 bed and pathologic nodal stage (ypN0) using Kaplan-Meier plots.

288 , prevalence- and bias-adjusted kappa value, Kaplan-Meier curves, and Cox proportional hazard models.

289 with that of an inverse probability-weighted Kaplan-Meier curve applied after treating bacteremia as

290 sion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model, and estimatio

291 nary revascularization) were calculated with Kaplan-Meier methods.

292 esion revascularization (TLR) estimated with Kaplan-Meier analysis, clinical and hemodynamic improvem

293 om from revascularization was estimated with Kaplan-Meier analysis.

294 dementia and parkinsonism was estimated with Kaplan-Meier analysis.

295 progression-free survival was estimated with Kaplan-Meier methods.

296 astasis-free survival were investigated with Kaplan-Meier curves and multivariable Cox models.

297 We measured IUC discontinuation rates with Kaplan-Meier estimates and Cox proportional hazards mode

298 lf-harm and risk factors for repetition with Kaplan-Meier methods and Cox proportional hazard models.

299 Inverse probability weighting was used with Kaplan-Meier analysis to determine amputation-free survi

300 Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5%